Comparison 6. Chemotherapy with docetaxel versus non‐docetaxel‐containing regimes.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Overall survival	8	2001	Hazard Ratio (Fixed, 95% CI)	0.86 [0.78, 0.95]
1.1 Substitutive comparisons	3	479	Hazard Ratio (Fixed, 95% CI)	1.05 [0.87, 1.27]
1.2 Additive comparisons	4	1466	Hazard Ratio (Fixed, 95% CI)	0.80 [0.71, 0.91]
1.3 Other comparisons	1	56	Hazard Ratio (Fixed, 95% CI)	0.80 [0.46, 1.39]
2 Tumour response	9	1820	Odds Ratio (M‐H, Random, 95% CI)	1.37 [1.03, 1.83]
2.1 Substitutive comparison	4	525	Odds Ratio (M‐H, Random, 95% CI)	1.03 [0.71, 1.50]
2.2 Additive comparison	4	1235	Odds Ratio (M‐H, Random, 95% CI)	1.83 [1.45, 2.32]
2.3 Other comparisons	1	60	Odds Ratio (M‐H, Random, 95% CI)	0.33 [0.12, 0.96]
3 Time to progression	2	360	Hazard Ratio (Random, 95% CI)	1.06 [0.85, 1.32]
4 Progression‐free survival	5	1498	Hazard Ratio (Random, 95% CI)	0.76 [0.63, 0.91]
4.1 Substitutive comparisons	1	119	Hazard Ratio (Random, 95% CI)	1.15 [0.77, 1.72]
4.2 Additive comparison (PFS)	3	1323	Hazard Ratio (Random, 95% CI)	0.70 [0.61, 0.81]
4.3 Other comparisons	1	56	Hazard Ratio (Random, 95% CI)	0.94 [0.55, 1.60]
5 Treatment‐related death	7	2113	Odds Ratio (M‐H, Fixed, 95% CI)	1.10 [0.55, 2.20]
6 Treatment discontinuation due to toxicity	5	1066	Odds Ratio (M‐H, Random, 95% CI)	0.81 [0.53, 1.25]